Eloxx Pharmaceuticals, Inc. logo

Eloxx Pharmaceuticals, Inc.(ELOX)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$13.15
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ELOX

11/13/2026: ELOX (1-star) is currently NOT-A-BUY. Pass it for now.

Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics that modulate ribosomes to address rare genetic diseases caused by nonsense mutations. Its primary clinical candidate, exaluren, represents the core growth opportunity as it advances through mid-stage trials for rare kidney disorders. Key strengths include an innovative scientific platform and recent regulatory advancements, though these are balanced by significant risks including a lack of commercial product revenue, high cash burn, and clinical trial uncertainty. The stock suits speculative growth investors comfortable with high volatility, who should closely monitor upcoming clinical data readouts and regulatory updates.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company offers high-growth potential tied to clinical catalysts, though it lacks commercial revenue.
Momentum investorStrong fit while signal remains positiveShort-term momentum can be sharp around clinical trial updates and regulatory announcements.
Value investorWeak fitThe absence of earnings and commercial revenues makes traditional value metrics inapplicable.
Dividend investorWeak fitThe company does not pay dividends and retains all capital for drug development.
Low-risk investorWeak fitClinical-stage biotechnology investing entails high clinical, regulatory, and financial volatility.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighStock prices fluctuate dramatically based on clinical trial announcements and sentiment.
Valuation riskMedium / highValuations are driven by speculative clinical potential rather than trailing fundamental earnings.
Competition risk (rare disease and genetic therapeutics)HighNumerous competitors are targeting rare genetic disorders with alternative genetic modalities.
Business qualityMediumThe platform is scientifically innovative, but clinical-stage operations carry inherent operational fragility.
Dividend incomeLow / noneNo dividend is distributed to shareholders.
Execution riskHighSuccess depends entirely on executing clinical trials successfully and securing regulatory approvals.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 53.08M USD
Price to earnings Ratio 3.74
1Y Target Price 37.5
Price to earnings Ratio 3.74
1Y Target Price 37.5
Volume (30-day avg) 25.2K shares
Beta -169204.95
52 Weeks Range 8.20 - 23.40
Updated Date 11/15/2026
52 Weeks Range 8.20 - 23.40
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) 3.52

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Insufficient Data
PRICE PATH

Insufficient Data

The stock demonstrates a Insufficient Data price path pattern.

Insufficient Data
PRICE STABILITY

Insufficient Data

The stock price exhibits a Insufficient Data stability pattern.

Analysis of Past Performance

Type Stock
Historic Profit -18.32%
Avg. Invested days 19
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ELOX receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
ELOX has moderate overall fundamentals (3 stars), with moderate financial health, weak growth momentum, and solid ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-90.7%), soft cash generation (FCF margin 0.0%), negative revenue growth (-100.0%).

Financial Health Rating

★★★★★
ELOX's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
ELOX's growth profile is soft, with the least-weak measure being free-cash-flow growth at -34.2% FY2025 versus FY2024. By comparison, while revenue growth (-100.0%, negative) and earnings growth (-90.7%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 78.9% and approximately 23.1% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 19.10% supports management-shareholder alignment.

Top 5 Institutional Investors

Nantahala Capital Management, LLC 19.82%
EcoR1 Capital, LLC 9.91%
Siren, L.L.C. 9.91%
Samsara BioCapital, LLC 9.91%
Aberdeen Group PLC 9.91%

Unit Economics (Per $1K Revenue)

★★★★★
ELOX generates approximately $0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
ELOX has a relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Therapeutic Drug Development (Pre-commercial)Future potential commercial sales or licensing milestones from drug candidates like exaluren.The company currently generates no commercial product revenue and relies on research funding or partnerships.

Valuation

Trailing PE 3.74
Forward PE -
Enterprise Value 48.69M
Price to Sales(TTM) -
Enterprise Value 48.69M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA 0.1
Shares Outstanding 4.04M
Shares Floating 932.58K
Shares Outstanding 4.04M
Shares Floating 932.58K
Percent Insiders 19.1
Percent Institutions 78.88

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.